317 related articles for article (PubMed ID: 24361534)
1. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
2. Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
Doi Y; Abu Lila AS; Matsumoto H; Okada T; Shimizu T; Ishida T
Int J Nanomedicine; 2016; 11():5573-5582. PubMed ID: 27822036
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
Nagao A; Abu Lila AS; Ishida T; Kiwada H
Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
[TBL] [Abstract][Full Text] [Related]
6. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
7. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose.
Nakamura H; Abu Lila AS; Nishio M; Tanaka M; Ando H; Kiwada H; Ishida T
J Control Release; 2015 Dec; 220(Pt A):406-413. PubMed ID: 26548975
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
11. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
12. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of liposomal l-OHP and PEGylated TS shRNA-lipoplex: A novel approach to enhance anti-tumor efficacy and reduce the immunogenic response to RNAi molecules.
Alaaeldin E; Abu Lila AS; Ando H; Fukushima M; Huang CL; Wada H; Sarhan HA; Khaled KA; Ishida T
J Control Release; 2017 Jun; 255():210-217. PubMed ID: 28461099
[TBL] [Abstract][Full Text] [Related]
15. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
[TBL] [Abstract][Full Text] [Related]
16. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
17. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
19. Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.
Bansal D; Gulbake A; Tiwari J; Jain SK
Int J Biol Macromol; 2016 Jan; 82():687-95. PubMed ID: 26464131
[TBL] [Abstract][Full Text] [Related]
20. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
Ando H
Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
